(Q35211282)

7 August 2017

1 reference

title

Fluoroquinolones in paediatrics: a risk for the patient or for the community? (English)

1 reference

7 August 2017

1 reference

2

Martin Chalumeau

1 reference

7 August 2017

Dominique Gendrel

1

1 reference

7 August 2017

Florence Moulin

series ordinal

3

1 reference

7 August 2017

Josette Raymond

series ordinal

4

1 reference

7 August 2017

publication date

1 September 2003

1 reference

Lancet Infectious Diseases

7 August 2017

published in

1 reference

7 August 2017

volume

3

1 reference

7 August 2017

issue

9

1 reference

7 August 2017

page(s)

537-546

1 reference

Quinolone arthropathy in animals versus children

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Fluoroquinolones in paediatrics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

New uses for new and old quinolones and the challenge of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Growth and joint symptoms in children treated with nalidixic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Tolerance and safety of ciprofloxacin in paediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Tolerability of fluoroquinolone antibiotics. Past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

A European study on the relationship between antimicrobial use and antimicrobial resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Fluoroquinolone resistance among Gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Epidemiology of quinolone resistance: Europe and North and South America.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Trends in bacterial resistance to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Quinolone resistance among Salmonella enterica from cattle, broilers, and swine in Denmark.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin in neonates and its possible adverse effect on the teeth

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Comparative tolerability of the newer fluoroquinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Side-effects of pefloxacin in idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Integrins: versatility, modulation, and signaling in cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Quinolones in children with invasive salmonellosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin safety in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Typhoid fever, ciprofloxacin and growth in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Safety of oral ciprofloxacin. An update based on clinical trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Use of fluoroquinolones as prophylactic agents in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Interaction between methotrexate and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin in neonatal Enterobacter cloacae septicaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

1 reference

7 January 2021

Ciprofloxacin for treatment of severe typhoid fever in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

A highly ceftriaxone-resistant Salmonella typhi in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Ciprofloxacin-resistant Salmonella typhi and treatment failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Intermediate susceptibility to ciprofloxacin in Salmonella typhi strains in India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Salmonella bacteraemia in sickle cell disease at King's College Hospital: 1976-1991.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Emergence of ciprofloxacin resistance during treatment of Salmonella osteomyelitis in three patients with sickle cell disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Eradication of convalescent-phase Salmonella carriage in children with two oral doses of pefloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Short-term pefloxacin therapy in Madagascan children with shigellosis due to multiresistant organisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Chronic otitis media treated topically with ciprofloxacin or tobramycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Sequential colonization by Streptococcus pneumoniae of healthy children living in an orphanage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

Widespread use of fluoroquinolones versus emerging resistance in pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900736-9

7 January 2021

10.1016/S1473-3099(03)00736-9

Identifiers

DOI

1 reference

7 August 2017

1 reference